,i #aagth ,,congress #ast ,session ,h4 ,r4 #bed ,,in ,,the ,,house ,,of ,,representatives ,january #aa1 #bjba,ms4 ,lee of ,california introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,public ,health ,service ,act to create a ,national ,neuromyelitis ,optica ,spectrum ,disorder ,consortium to provide grants1 coordinate synergistic research1 and targeted therapy with respect to the causes of1 and risk factors associated with1 neuromyelitis optica spectrum disorder1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,neuromyelitis ,optica ,spectrum ,disorder ,consortium ,act4 #b4 ,findings ,congress finds the following3 7#a7 ,neuromyelitis optica spectrum disorder 7in this section and section #c referred to as ,,nmosd7 is a devastating neurologic disease leading to blindness1 paralysis1 and premature death4 7#b7 ,there are an estimated #af1jjj to #ag1jjj people with ,,nmosd in the ,united ,states and more than a quarter-million patients worldwide4 7#c7 ,women are affected up to #g times more than men1 and ,afro-,caribbeans and ,latino persons are about #b4e times more predisposed to ,,nmosd than ,caucasians4 ,the reasons why ,blacks and ,hispanics are disproportionately affected cannot be fully understood without further studies4 ,furthermore1 why ,,nmosd disproportionately occurs in females is unknown4 7#d7 ,the average age at diagnosis is approximately #ce to #de years1 a peak window of time that further compounds the burden of ,,nmosd on parenthood and careers of women and men4 ,the age range of ,,nmosd patients is broad and includes children as young as #c years of age and adults as old as #ij4 7#e7 ,,nmosd imposes substantial costs for affected patients and their families both in financial costs such those associated with medical care1 prescription medicines1 and emergency room visits1 as well as in opportunity costs such as its negative impact on maintaining gainful employment or attending school or career development programs4 7#f7 ,the origins of ,,nmosd are unknown1 but it is hypothesized to be autoimmune in nature4 ,collectively1 autoimmune diseases currently affect approximately #a in #aj ,americans4 ,without a clear understanding of the causes of ,,nmosd1 development of cures that save and improve lives and reduce the substantial associated health care costs will not be possible4 7#g7 ,despite the recent ,food and ,drug ,administration approval of three medications for ,,nmosd1 there remains an unmet need for more effective and safe therapies to spare these patients from this recurrent disease with its accumulating neurologic disability4 7#h7 ,because of their relatively low overall incidence1 orphan diseases like ,,nmosd frequently do not receive sufficient attention and research funding4 ,of special importance is the opportunity for the remarkable progress made recently regarding ,,nmosd to serve as-- 7,a7 a model for solutions to rare and immunologic diseases2 and 7,b7 an exemplary therapeutic disease target for immunosuppressive therapies and for determining vaccination benefits and risks relative to ,,covid-#ai4 7#i7 ,no single institution has a sufficient number of patients to independently conduct research that will adequately address the cause1 prevention1 treatment1 and potential cure of ,,nmosd4 ,furthermore1 there is a paucity of resources available for regenerative medicine research in ,,nmosd that will be required to repair optic nerve and spinal cord damage caused by ,,nmosd and thus to restore health4 7#aj7 ,there has been no comprehensive study analyzing all relevant clinical1 biological1 and epidemiological aspects of ,,nmosd to identify potential risk factors and biomarkers for ,,nmosd4 7#aa7 ,we can apply our understanding of ,,nmosd to the study of other autoimmune diseases1 including type #a diabetes mellitus1 rheumatoid arthritis1 psoriasis1 multiple sclerosis1 systemic lupus erythematosus1 and many others4 #c4 ,sense of ,congress ,it is the sense of ,congress that-- 7#a7 there is a need to establish and coordinate a synergistic1 multicenter research effort based on collaboration between regional consortia and governmental and nongovernmental entities in order to-- 7,a7 comprehensively study the causes of ,,nmosd2 7,b7 identify potential biomarkers of disease activity2 7,c7 leverage recent efforts in developing approved therapies for ,,nmosd as a model for developing breakthrough therapies for other autoimmune diseases2 and 7,d7 highlight ,,nmosd as a model disease to better understand the potential benefits and risks of immunosuppressive therapy and innovative vaccine strategies targeting ,,covid-#ai2 7#b7 there is a need to encourage a collaborative effort among academic medical centers comprising epidemiological study groups capable of gathering comprehensive and detailed information for each patient enrolled in those groups2 and 7#c7 the effort referred to in paragraph 7#b7 should facilitate investigation of environmental1 nutritional1 genetic1 and treatment factors with respect to the pathological and epidemiological characteristics of ,,nmosd4 #d4 ,establishment of the ,national ,neuromyelitis ,optica ,spectrum ,disorder ,consortium ,part ,b of title ,,iv of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bhd et seq47 is amended by adding after section #dji;,j the following new section3 #dji,k4 ,national ,neuromyelitis ,optica ,spectrum ,disorder ,consortium 7a7 ,establishment of the ,national ,neuromyelitis ,optica ,spectrum ,disorder ,consortium 7#a7 ,in general ,not later than #a year after the date of the enactment of this section1 the ,secretary1 acting through the ,director of ,,nih1 and in coordination with the ,director of the ,national ,institute on ,minority ,health and ,health ,disparities1 shall establish1 administer1 and coordinate a ,national ,neuromyelitis ,optica ,spectrum ,disorder ,consortium 7in this section referred to as the ,,nmosd ,consortium7 for the purposes described in paragraph 7#b74 7#b7 ,purposes ,the purposes of the ,,nmosd ,consortium shall be the following3 7,a7 ,providing grants of not less than #e-years' duration to eligible consortia for the purpose of conducting research with respect to the causes of1 risk factors and biomarkers associated with1 and treatment of and comorbidities associated with1 ,,nmosd4 7,b7 ,assembling a panel of experts to provide1 with respect to research funded by the ,,nmosd ,consortium1 ongoing guidance and recommendations for the development of the following3 7i7 ,a standardized study design1 including adaptive clinical trial structures that may quickly and efficiently evaluate multiple treatment regimens to optimize precision and effectively assess personalized medicine in rare and immunologic diseases4 7ii7 ,standard protocols1 methods1 procedures1 and assays for collecting from individuals enrolled as study participants a minimum dataset that includes the following3 7,i7 ,complete medical history1 including autoimmune and nonautoimmune comorbidities4 7,,ii7 ,neurologic examination and standardization of critical clinical outcomes such as the definition and adjudication of relapse in ,,nmosd4 7,,iii7 ,biospecimens1 including serum1 blood cells1 cerebrospinal fluid1 ,,dna1 and ,,rna4 7,,iv7 ,radiological data1 including magnetic resonance imaging 7,,mri7 and optical coherence tomography1 among other modalities4 7iii7 ,specific analytical methods for examining data1 including bioinformatic and computational modeling for deterministic as well as predictive capabilities4 7iv7 ,provisions for consensus review of enrolled cases1 including clinical trial data as well as off-label drug use and epidemiologic studies that would be offer greater insights if considered in aggregate than alone4 7v7 ,an integrated data collection network1 including registry and other activities that improve scientific and clinical efficiencies in achieving the purposes outlined in this paragraph4 7,c7 ,designating a consortium-dedicated laboratory to collect1 analyze1 and aggregate data with respect to research funded by the ,,nmosd ,consortium and to make such data and analysis available to researchers4 7#c7 ,eligible consortia ,to be eligible for a grant under this section1 a consortium shall demonstrate the following3 7,a7 ,the consortium has the capability to enroll as research participants a minimum of #be individuals with a diagnosis of ,,nmo from the consortium's designated catchment area4 7,b7 ,the designated catchment area of the consortium does not overlap with the designated catchment area of another consortium already receiving a grant under this section4 7#d7 ,report ,not later than #a year after the date of the enactment of this section1 and annually thereafter1 the ,secretary1 acting through the ,director of ,,nih1 shall submit to ,congress a report with respect to the ,,nmosd ,consortium1 to be made publicly available1 including a summary of research funded by the ,,nmosd ,consortium and a list of consortia receiving grants through the ,,nmosd ,consortium4 ,at the discretion of the ,secretary1 such report may be combined with other similar or existing reports4 7#e7 ,authorization of appropriations 7,a7 ,in general ,there is authorized to be appropriated #be1jjj1jjj for each of fiscal years #bjba through #bjbd1 to remain available until expended1 to carry out this section4 7,b7 ,sense of ,congress ,it is the sense of ,congress that funds appropriated to carry out this section should be in addition to funds otherwise available or appropriated to carry out the activities described in this section4 7b7 ,definitions ,for purposes of this section3 7#a7 ,catchment area ,the term catchment area means a defined area for which population data are available4 7#b7 ,consortium ,the term consortium means a partnership of two or more universities1 health care organizations1 or government agencies1 or any combination of such entities1 serving a designated catchment area4 4